Phase II trial of subcutaneous injections of interleukin-2 for the treatment of mycosis fungoides or the sezary syndrome.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Interleukin-2 (Primary)
- Indications Mycosis fungoides; Sezary syndrome
- Focus Therapeutic Use
- 06 Jun 2012 Biomarkers information updated
- 13 Jul 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 13 Jul 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.